Previous Close | 62.18 |
Open | 62.18 |
Bid | 59.24 x 100 |
Ask | 59.98 x 100 |
Day's Range | 58.11 - 62.41 |
52 Week Range | 11.85 - 67.21 |
Volume | |
Avg. Volume | 183,483 |
Market Cap | 783.707M |
Beta (5Y Monthly) | 2.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -18.69 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 138.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for PRAX
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funde
BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering
Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.